Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.50 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056368 | 0.90 | MEN1 (0.55) | PTPN22PTPN12MEN1POLBKMT2A | |
| SCHEMBL13056349 | 0.90 | MEN1 (0.55) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL13056351 | 0.83 | AKR1B1 (0.60) | PTPN1PTPN22MEN1POLBKMT2A | |
| SCHEMBL1906468 | 0.76 | PTPN1 (0.56) | PTPN1PTPN22PTPN12MEN1POLB | |
| SCHEMBL1906469 | 0.76 | PTPN1 (0.56) | PTPN1PTPN22PTPN12MEN1POLB | |
| SCHEMBL13056331 | 0.75 | MAP3K5 (0.78) | PTPN22 | |
| SCHEMBL8594085 | 0.75 | MAP3K5 (0.78) | PTPN22 | |
| SCHEMBL8594082 | 0.75 | MAP3K5 (0.78) | PTPN22 | |
| SCHEMBL13056346 | 0.73 | PTPN22 (0.67) | PTPN1PTPN22PTPN12MEN1POLB | |
| SCHEMBL3178417 | 0.73 | PTPN1 (0.93) | PTPN1MEN1POLBKMT2ADNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-25 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718680-B2 | Inhibition of lethal factor protease activity from anthrax toxin | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298390-A1 | INHIBITION OF LETHAL FACTOR PROTEASE ACTIVITY FROM ANTHRAX TOXIN | APAF1, ANTXR2, SERPINB1 | PTPN1 3550/4885PTPN22 3261/4885PTPN12 3273/4885 |
| US-20080033025-A1 | Inhibition of lethal factor protease activity from anthrax toxin | APAF1, ANTXR2, SERPINB1 | PTPN1 3550/4885PTPN22 3261/4885PTPN12 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.